Aktis Oncology, Inc. Announces Board Changes

Published: 2026-04-16 09:20:29 ET AKTS

Published on 04/16/2026 at 09:20 am EDT

Aktis Oncology, Inc. announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the company?s newly established Science and Technology Committee of the Board of Directors. Dr. Gormley brings more than three decades of biopharmaceutical leadership across research and development, executive leadership, and board service. Most recently, Dr. Gormley served as Senior Executive Officer and Global Head of Research and Development at Daiichi Sankyo Co.

Ltd., and as Executive Chairman and President of Daiichi Sankyo, Inc. In these roles, he led the global R&D strategy and oversaw the development of a broad and diversified pipeline, including the successful build-out of Daiichi Sankyo?s ADC platform. Prior to Daiichi Sankyo, Dr. Gormley held senior leadership positions at several global pharmaceutical companies. He served as Chief Medical Officer at AstraZeneca and as Global Head of Clinical Development and Medical Affairs at Novartis, where he led late-stage development and medical strategy across multiple programs. Earlier in his career, he held senior clinical development roles at Merck.

Dr. Gormley holds an MD and a PhD from the University of Chicago and completed his training at UCLA and New York University leading to board certification in pediatrics and pediatric endocrinology. Concurrent with Dr. Gormley?s appointment to Aktis? Board of Directors, current Board members Helen Kim and Oleg Nodelman plan to step down from Aktis?

Board of Directors, effective May 20, 2026.